International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010).
A panel of international breast cancer experts formulated a declaration of consensus regarding many key issues in the use of primary systemic therapy (PST) either in clinical routine or research practice. The attainment of pathological complete response (pCR), defined as no residual invasive tumor i...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2011
|
| _version_ | 1797096184856182784 |
|---|---|
| author | Berruti, A Generali, D Kaufmann, M Puztai, L Curigliano, G Aglietta, M Gianni, L Miller, W Untch, M Sotiriou, C Daidone, M Conte, P Kennedy, D Damia, G Petronini, P Di Cosimo, S Bruzzi, P Dowsett, M Desmedt, C Mansel, R Olivetti, L Tondini, C Sapino, A Fenaroli, P Tortora, G |
| author_facet | Berruti, A Generali, D Kaufmann, M Puztai, L Curigliano, G Aglietta, M Gianni, L Miller, W Untch, M Sotiriou, C Daidone, M Conte, P Kennedy, D Damia, G Petronini, P Di Cosimo, S Bruzzi, P Dowsett, M Desmedt, C Mansel, R Olivetti, L Tondini, C Sapino, A Fenaroli, P Tortora, G |
| author_sort | Berruti, A |
| collection | OXFORD |
| description | A panel of international breast cancer experts formulated a declaration of consensus regarding many key issues in the use of primary systemic therapy (PST) either in clinical routine or research practice. The attainment of pathological complete response (pCR), defined as no residual invasive tumor in the surgical specimens both in breast and in axillary nodes, is one of the main goals of PST, and pCR can be used as the primary objective in prospective clinical trials. However, pCR is not a reliable endpoint with all treatment approaches, and alternatives such as Ki67 index of the residual invasive disease or after 2 weeks of PST are also potential endpoints. PST has several advantages: breast conservation and the unique opportunity to obtain information on the interaction between treatment and tumor biology. Changes in tumor biology after PST are an early phenomenon; so, an additional core biopsy performed after 14 days from treatment start should be considered in clinical trials. |
| first_indexed | 2024-03-07T04:38:28Z |
| format | Journal article |
| id | oxford-uuid:d0ca9259-45e5-4d49-8943-b22ad8f8974e |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:38:28Z |
| publishDate | 2011 |
| record_format | dspace |
| spelling | oxford-uuid:d0ca9259-45e5-4d49-8943-b22ad8f8974e2022-03-27T07:52:36ZInternational expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010).Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:d0ca9259-45e5-4d49-8943-b22ad8f8974eEnglishSymplectic Elements at Oxford2011Berruti, AGenerali, DKaufmann, MPuztai, LCurigliano, GAglietta, MGianni, LMiller, WUntch, MSotiriou, CDaidone, MConte, PKennedy, DDamia, GPetronini, PDi Cosimo, SBruzzi, PDowsett, MDesmedt, CMansel, ROlivetti, LTondini, CSapino, AFenaroli, PTortora, GA panel of international breast cancer experts formulated a declaration of consensus regarding many key issues in the use of primary systemic therapy (PST) either in clinical routine or research practice. The attainment of pathological complete response (pCR), defined as no residual invasive tumor in the surgical specimens both in breast and in axillary nodes, is one of the main goals of PST, and pCR can be used as the primary objective in prospective clinical trials. However, pCR is not a reliable endpoint with all treatment approaches, and alternatives such as Ki67 index of the residual invasive disease or after 2 weeks of PST are also potential endpoints. PST has several advantages: breast conservation and the unique opportunity to obtain information on the interaction between treatment and tumor biology. Changes in tumor biology after PST are an early phenomenon; so, an additional core biopsy performed after 14 days from treatment start should be considered in clinical trials. |
| spellingShingle | Berruti, A Generali, D Kaufmann, M Puztai, L Curigliano, G Aglietta, M Gianni, L Miller, W Untch, M Sotiriou, C Daidone, M Conte, P Kennedy, D Damia, G Petronini, P Di Cosimo, S Bruzzi, P Dowsett, M Desmedt, C Mansel, R Olivetti, L Tondini, C Sapino, A Fenaroli, P Tortora, G International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). |
| title | International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). |
| title_full | International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). |
| title_fullStr | International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). |
| title_full_unstemmed | International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). |
| title_short | International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). |
| title_sort | international expert consensus on primary systemic therapy in the management of early breast cancer highlights of the fourth symposium on primary systemic therapy in the management of operable breast cancer cremona italy 2010 |
| work_keys_str_mv | AT berrutia internationalexpertconsensusonprimarysystemictherapyinthemanagementofearlybreastcancerhighlightsofthefourthsymposiumonprimarysystemictherapyinthemanagementofoperablebreastcancercremonaitaly2010 AT generalid internationalexpertconsensusonprimarysystemictherapyinthemanagementofearlybreastcancerhighlightsofthefourthsymposiumonprimarysystemictherapyinthemanagementofoperablebreastcancercremonaitaly2010 AT kaufmannm internationalexpertconsensusonprimarysystemictherapyinthemanagementofearlybreastcancerhighlightsofthefourthsymposiumonprimarysystemictherapyinthemanagementofoperablebreastcancercremonaitaly2010 AT puztail internationalexpertconsensusonprimarysystemictherapyinthemanagementofearlybreastcancerhighlightsofthefourthsymposiumonprimarysystemictherapyinthemanagementofoperablebreastcancercremonaitaly2010 AT curiglianog internationalexpertconsensusonprimarysystemictherapyinthemanagementofearlybreastcancerhighlightsofthefourthsymposiumonprimarysystemictherapyinthemanagementofoperablebreastcancercremonaitaly2010 AT agliettam internationalexpertconsensusonprimarysystemictherapyinthemanagementofearlybreastcancerhighlightsofthefourthsymposiumonprimarysystemictherapyinthemanagementofoperablebreastcancercremonaitaly2010 AT giannil internationalexpertconsensusonprimarysystemictherapyinthemanagementofearlybreastcancerhighlightsofthefourthsymposiumonprimarysystemictherapyinthemanagementofoperablebreastcancercremonaitaly2010 AT millerw internationalexpertconsensusonprimarysystemictherapyinthemanagementofearlybreastcancerhighlightsofthefourthsymposiumonprimarysystemictherapyinthemanagementofoperablebreastcancercremonaitaly2010 AT untchm internationalexpertconsensusonprimarysystemictherapyinthemanagementofearlybreastcancerhighlightsofthefourthsymposiumonprimarysystemictherapyinthemanagementofoperablebreastcancercremonaitaly2010 AT sotiriouc internationalexpertconsensusonprimarysystemictherapyinthemanagementofearlybreastcancerhighlightsofthefourthsymposiumonprimarysystemictherapyinthemanagementofoperablebreastcancercremonaitaly2010 AT daidonem internationalexpertconsensusonprimarysystemictherapyinthemanagementofearlybreastcancerhighlightsofthefourthsymposiumonprimarysystemictherapyinthemanagementofoperablebreastcancercremonaitaly2010 AT contep internationalexpertconsensusonprimarysystemictherapyinthemanagementofearlybreastcancerhighlightsofthefourthsymposiumonprimarysystemictherapyinthemanagementofoperablebreastcancercremonaitaly2010 AT kennedyd internationalexpertconsensusonprimarysystemictherapyinthemanagementofearlybreastcancerhighlightsofthefourthsymposiumonprimarysystemictherapyinthemanagementofoperablebreastcancercremonaitaly2010 AT damiag internationalexpertconsensusonprimarysystemictherapyinthemanagementofearlybreastcancerhighlightsofthefourthsymposiumonprimarysystemictherapyinthemanagementofoperablebreastcancercremonaitaly2010 AT petroninip internationalexpertconsensusonprimarysystemictherapyinthemanagementofearlybreastcancerhighlightsofthefourthsymposiumonprimarysystemictherapyinthemanagementofoperablebreastcancercremonaitaly2010 AT dicosimos internationalexpertconsensusonprimarysystemictherapyinthemanagementofearlybreastcancerhighlightsofthefourthsymposiumonprimarysystemictherapyinthemanagementofoperablebreastcancercremonaitaly2010 AT bruzzip internationalexpertconsensusonprimarysystemictherapyinthemanagementofearlybreastcancerhighlightsofthefourthsymposiumonprimarysystemictherapyinthemanagementofoperablebreastcancercremonaitaly2010 AT dowsettm internationalexpertconsensusonprimarysystemictherapyinthemanagementofearlybreastcancerhighlightsofthefourthsymposiumonprimarysystemictherapyinthemanagementofoperablebreastcancercremonaitaly2010 AT desmedtc internationalexpertconsensusonprimarysystemictherapyinthemanagementofearlybreastcancerhighlightsofthefourthsymposiumonprimarysystemictherapyinthemanagementofoperablebreastcancercremonaitaly2010 AT manselr internationalexpertconsensusonprimarysystemictherapyinthemanagementofearlybreastcancerhighlightsofthefourthsymposiumonprimarysystemictherapyinthemanagementofoperablebreastcancercremonaitaly2010 AT olivettil internationalexpertconsensusonprimarysystemictherapyinthemanagementofearlybreastcancerhighlightsofthefourthsymposiumonprimarysystemictherapyinthemanagementofoperablebreastcancercremonaitaly2010 AT tondinic internationalexpertconsensusonprimarysystemictherapyinthemanagementofearlybreastcancerhighlightsofthefourthsymposiumonprimarysystemictherapyinthemanagementofoperablebreastcancercremonaitaly2010 AT sapinoa internationalexpertconsensusonprimarysystemictherapyinthemanagementofearlybreastcancerhighlightsofthefourthsymposiumonprimarysystemictherapyinthemanagementofoperablebreastcancercremonaitaly2010 AT fenarolip internationalexpertconsensusonprimarysystemictherapyinthemanagementofearlybreastcancerhighlightsofthefourthsymposiumonprimarysystemictherapyinthemanagementofoperablebreastcancercremonaitaly2010 AT tortorag internationalexpertconsensusonprimarysystemictherapyinthemanagementofearlybreastcancerhighlightsofthefourthsymposiumonprimarysystemictherapyinthemanagementofoperablebreastcancercremonaitaly2010 |